Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TLR3 | O15455 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568015 | 0.91 | MAPT (0.48) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL28834633 | 0.88 | CYP19A1 (0.56) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL6566656 | 0.87 | CYP19A1 (0.56) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL6564473 | 0.87 | CYP19A1 (0.56) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL6564609 | 0.87 | MAPT (0.48) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL28101471 | 0.86 | CYP19A1 (0.55) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL28216463 | 0.85 | CYP19A1 (0.57) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL6566711 | 0.85 | CYP19A1 (0.46) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL28101489 | 0.81 | CYP19A1 (0.59) | CYP19A1MAPTLMNARAB9ANPC1 | |
| SCHEMBL30354920 | 0.80 | CYP19A1 (0.62) | CYP19A1MAPTLMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | CYP19A1 611/4885MAPT 4743/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.